Drug Regulatory Authority of Pakistan

The Honorable Prime Minister of Pakistan formally launched DRAP’s “Digital System for Licensing & Registration of Medical Devices” today. The Federal Minister for National Health Services, Regulations & Coordination warmly welcomed the Prime Minister at the inauguration ceremony.

#research #Grants #DRAP

🇵🇰🇲🇻 DRAP formally hosted H.E. Ms. Aminath Shirna, State Minister for Health, #Maldives, for discussions on advancing regulatory frameworks and quality assurance. This visit signifies a crucial step towards strengthening healthcare systems in both nations. #HealthCooperation

Dr.obaidullah CEO @DRA_Pakistan expressing his views on falsified medicines in a panel discussion at 78th World Health Assembly on 24-May-2025 at 1600 PST. Please click in following link 👇 youtube.com/live/j4WTHwx17J4….

Dr. Obaidullah has been appointed as the new CEO of Drug Regulatory Authority of Pakistan. With his exceptional leadership and forward-thinking vision, we’re confident DRAP will thrive and set new standards as a model regulatory authority. Here’s to a bright future ahead!" 🎉👏

The DRAP is taking steps to ensure that lifesaving medicines are available to everyone.

Drug Regulatory Authority of Pakistan (DRAP) strives to provide public with safe, effective, and quality drugs. Information on the activities of the Division of Pharmaceutical Evaluation and Registration can be found here 👇

مردانہ طرز کے گنجے پن کے لیے استعمال ہونے والی دوا (Finasteride) نوجوانوں میں خودکشی کے خیال/خیالات اور خود کو چوٹ لگنے کا ممکنہ خطرہ رکھتی ہے۔ مزید تفصیلات کے لیے یہاں کلک کریں: dra.gov.pk/safety_info/safet…

Finasteride medicine that is used for male pattern baldness has a Potential risk of suicidal ideation/thoughts & self-injury especially in young people. Click here for further details: dra.gov.pk/safety_info/safet…

مردانہ طرز کے گنجے پن کے لیے استعمال ہونے والی دوا (Finasteride) نوجوانوں میں خودکشی کے خیال/خیالات اور خود کو چوٹ لگنے کا ممکنہ خطرہ رکھتی ہے۔ مزید تفصیلات کے لیے یہاں کلک کریں: dra.gov.pk/safety_info/safet…

As per DRAP Safety Alert No 28, co-administration of Hydroxychloroquine or Chloroquine, with systemic Macrolide Antibiotics may lead to an increased risk of cardiovascular events due to potential interaction. Further detail on the website: dra.gov.pk/safety_info/safet…

According to the DRAP Safety Alert No 27, Pregabalin use during pregnancy may increase the risk of major birth defects in infants. Further detail on the website: dra.gov.pk/safety_info/safet…

Safety Alert 26: The National Pharmacovigilance Centre, DRAP issued a safety alert of risk of reduced vitamin B12 level with metformin and metformin-containing medicines. The alert is available on the official website: #Pharmacovigilance #drugsafety dra.gov.pk/wp-content/upload…

Safety Alert No. 25: Risk of Severe Cutaneous Adverse Reactions (SCARs) with Atezolizumab is now available on the drap website. #Pharmacovigilance #drugsafety dra.gov.pk/wp-content/upload…

Safety Alter No: 24. PRAEC committee of the DRAP issued a safety Alert on the risk of sinus bradycardia with Remdesivir: dra.gov.pk/safety_info/safet…

Drug safety update from the National Pharmacovigilance Centre, DRAP: Risk of hypothyroidism in babies and young children with iodinated contrast Media (ICM) injections: dra.gov.pk/safety_info/safet…

Safety Alter No: 22. Risk of serious bowel complications with clozapine is now available on DRAP website. For further details click here: dra.gov.pk/safety_info/safet…